Description

Bind Bio Myo-Inositol Trispyrophosphate (ITPP)

Myo-Inositol Trispyrophosphate (ITPP)

Myo-inositol trispyrophosphate (ITPP) is a new chemical that was created to improve the delivery of oxygen to cells that are low on oxygen [R]. Hypoxic conditions happen when there is inadequate oxygen delivery to some parts of the body. The above-mentioned event might happen in cases of heart disease, tumors, or other long-lasting health problems [R]. The protein hemoglobin, which moves oxygen around in red blood cells, is changed by ITPP. More oxygen can be released from hemoglobin to cells that need it because of this change. The extra oxygen might make the tissues healthier and better able to repair themselves. With this function, ITPP becomes an interesting area of study for dealing with diseases caused by low oxygen levels.

Bind Bio offers Myo-Inositol Trispyrophosphate (ITPP) in liquid form. A vial contains 30 ml of ITPP, 33 mg per ml, totaling 1000 mg.

How do Myo-Inositol Trispyrophosphate (ITPP) treatment work?

ITPP, or myo-inositol trispyrophosphate, has shown promise as a possible way to treat cancer. Animal tests show that it might work well on its own or with treatment. Allosteric effectors, like ITPP, change the structure of hemoglobin. Because of this change, hemoglobin can hold onto oxygen less tightly. This lets red blood cells send more oxygen to tissues. When oxygen levels are high, tumors do not usually grow very well. ITPP may slow tumor growth by increasing the flow of oxygen. It might also help balance blood vessels around tumors by lowering HIFs and VEGF, which cause blood vessels to grow in an abnormal way. ITPP might be a useful way to lower tumor hypoxia, or low oxygen in tumors, because it increases oxygen release and keeps blood flow steady [R].    

Properties

ITPP

Table Source: [R]

Potential Benefits of Myo-Inositol Trispyrophosphate (ITPP)

Anti Tumor Properties and Hypoxia

ITTP is famous for being able to fight hypoxic tumors [R]. Several studies back this up. One study in rodent tumor models showed that ITPP decreased the amount of tumors, and effectively stopped the hypoxic response [R]. In preclinical models, more action against tumour oxygenation was seen as well. This was seen in around 60% of people who had ITPP treatment. There is also a link between ITPP and how well subjects respond to and get better after administration. [R]

Heart Disease Treatment

The body needs a lot of oxygen to keep tissues, like the heart, working well. When oxygen is low, it can cause heart problems, like coronary artery disease and heart failure. Hemoglobin in red blood cells usually carries oxygen to tissues, releasing it where it’s needed. ITPP has shown promising results and is now being considered for human heart studies because of its safety. Research shows it may improve oxygen in heart tissue, boost exercise ability, and protect the heart from damage [R][R][R]. This shows ITTP potential in treating cardiovascular diseases such as pulmonary hypertension, myocardial hypoxia, and other conditions that require modulation of hemoglobin.

Enhance Exercise Capacity

A study induced heart failure in rats.  Adding a synthetic chemical that alters hemoglobin to skeletal muscle improved oxygen delivery without changing the properties of the muscle, according to the study. Therefore, the mice did better on the run even though their hearts were not working as well [R]. In another study, ITPP increased exercise capacity by improving oxygen delivery to muscles. In normal mice, ITPP raised hemoglobin’s ability to release oxygen, boosting exercise capacity by 57%. In mice with severe heart failure, it increased exercise performance by 63% [R].  This suggests that ITPP could be a potential treatment for improving exercise capacity in heart failure patients.

Side Effects and Safety Considerations

ITPP has been tested on test subjects with advanced cancer and was found to be well accepted. There were no serious adverse effects. During clinical studies, however, some side effects were seen [R].  Minor effect of ITPP :

• Hypercalcemia (59.4%): This is because ITPP binds calcium, and calcium chloride was added to keep the balance while the drug was being infused.
• There are mild deficits in magnesium and phosphate levels, which are called hypomagnesemia and hypophosphatemia (28.1%).
• There was mild hypertension in a few test subjects, which was probably caused by the higher blood volume during the infusion.

Even with these side effects, ITPP was well accepted, and test subjects stayed symptom-free with little help. Since it did not have a big effect on myocardial contractility or arterial blood pressure, it looks like a good way to improve oxygen delivery in study settings. Further studies are needed to fully understand its effects and confirm its potential therapeutic use in response to irradiation.

Why Choose Bind Bio to buy Myo-Inositol Trispyrophosphate (ITPP)?

Bind Bio SARM stack is your best choice for buying ITPP. Why? We have carefully selected reliable suppliers for our research chemicals due to our stringent standards. For the benefit of our clients, we pulled off these by giving equal attention to pricing and quality. We choose suppliers who have a wide variety of compounds, including peptides, SARMS, nootropics, and more. We provide not just one type but all kinds of forms (powder, tablet, etc) to suit your research needs. 

Meeting and passing stringent quality control standards is crucial to Bind Bio. We have selected IronMountainLabz, PureRawz and BehemothLabz as our research chemical suppliers. These top-tier vendors were chosen for their quality and seamless process. We also took into consideration its quality service on fast shipping, receiving payment, and after-sale.

Disclaimer

Bind bio provides general information only. We strive for precision and dependability, but we cannot guarantee the information’s completeness, reliability, appropriateness, or availability for any purpose. You assume the risk of using such information.

The content on Bind bio should not replace nutrition, supplement , medical advice, diagnosis, or treatment. Consult your doctor or other certified health expert with any medical questions. Professional medical advice should never be delayed based on Bind bio information.

Bind bio may include hyperlinks to external websites that are not governed or managed by our organization. We do not exert control over the nature, content, or availability of those sites. The presence of links , clinical trials, does not inherently suggest a recommendation or endorsement articulated within those links.

Under no circumstances shall Bind bio be held responsible for any loss or damage, including indirect or consequential losses, resulting from data loss or profits associated with the utilization of this website.

This disclaimer may be modified or amended at any time without prior notice. By persisting in the use of Bind bio, you acknowledge and consent to adhere to the stipulations outlined in this disclaimer. Should you find these terms unacceptable, we kindly ask that you do not utilize our website.

FAQ

Is Myo-Inositol Trispyrophosphate (ITPP) Liquid safe?

Myo-Inositol trispyrophosphate hexasodium salt has been shown to be well-tolerated in research settings, with no severe toxic effects reported. While ITPP appears safe in these settings, its long-term effects and full safety profile are still being studied. Further research is necessary to confirm its safety for broader use.

Is ITPP banned?

Yes, big sports organizations like the World Anti-Doping Agency (WADA) do not allow Myo-Inositol Trispyrophosphate (ITPP) because it can improve exercise performance. However, it can still be used in research settings, particularly for studying its effects on solid tumors in vivo, pancreatic cancer, and chemotherapy.